15

25

WE CLAIM:

Claim 1. A method for non-alimentary nutrition comprising administering to a patient in need of nutrition a pharmaceutical composition comprising a source of nutrients and one or more insulinotropic peptides.

- Claim 2. A method according to claim 1 wherein the source of nutrients is a source of carbohydrates.
- 10 Claim 3. A method according to claim 2 wherein the source of carbohydrate is a hexose, pentose, hexose alcohol, pentose alcohol, or any combination thereof.
 - Claim 4. A method according to claim 3 wherein the source of carbohydrate is glucose, fructose, galactose, zylito, mannitol, sorbitol, or any combination thereof.
 - Claim 5. A method according to claim 1 wherein the source of nutrients is one or more assimilable amino acids, lipids, free fatty acids, mono- or diglycerides or glycerol.
- Claim 6. A method according to claim 2 wherein the administration of the source of carbohydrate to the patient produces a blood glucose level in the patient of no more than from about 80 to 180 mg glucose per deciliter of blood and the rate of administration of the source of carbohydrate is calculated to deliver up to about 1000 g of glucose or its equivalent per patient per day.
 - Claim 7. A method according to claim 1 wherein the administration of the insulinotropic peptide or peptides produces a blood level of the peptide or peptides in the range of 1 pmol per L to 1 mmol per L of blood plasma.

5

10

15

25

Claim 8. A method according to claim 1 wherein the insulinotropic peptide is GLP-1, GIP, GLP-1 (7-34), GLP-1 (7-35), GLP-1 (7-36), GLP-1 (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the C-terminus ketone modifications thereof, the N-terminus modifications thereof or any mixture thereof.

- Claim 9. A method according to claim 2 wherein the pharmaceutical composition comprises the source of carbohydrate in a first aqueous medium and one or more insulinotropic peptides in a second aqueous medium or in a pharmaceutically acceptable solid or gel tab or sustained release matrix.
- Claim 10. A pharmaceutical composition comprising a source of nutrients and one or more insulinotropic peptides in combined or separate form.
- Claim 11. A pharmaceutical composition according to claim 10 wherein the source of nutrients is a source of carpohydrates.
- Claim 12. A pharmaceutical composition according to claim 11 wherein the source of carbohydrate is present at a concentration of about a 2% to about a 50% by weight of glucose or its equivalent per L.
 - Claim 13. A composition according to claim 10 wherein the insulinotropic peptide or peptides are present at a concentration of about 1 nmol per L to about 1 mmol per L.
 - Claim 14. A pharmaceutical composition comprising a kit containing a first aqueous mixture of a source of nutrients contained in a form for parenteral administration and a second aqueous mixture or solid or gel tab or sustained release

5

10

matrix of one or more insulinotropic peptides contained in a form for parenteral administration.

Claim 15. Use of a pharmaceutical composition according to claim 10 for nutrition of a patient.

Claim 16. Manufacture of a pharmaceutical composition for use in nutrition of a patient comprising preparation of a pharmaceutically acceptable formulation of a source of nutrients and preparation of a pharmaceutically acceptable formulation of one or more insulinotropic peptides.

add add